Ovandrotone albumin
immunogen and vaccine against androstenedione
Ovandrotone albumin (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name) (brand names Fecundin, Ovastim), also known as polyandroalbumin, as well as ovandrotone:human serum albumin conjugate, is an immunogen and vaccine against androstenedione that is used in veterinary medicine to increase the ovulation rate and number of lambs born to ewes. It is a conjugate of ovandrotone (androstenedione-7α-carboxyethylthioether) and human serum albumin. The drug was developed by 1981 and was introduced in Australia and New Zealand in 1983.
Ovandrotone albumin produces transient immunity against androstenedione, and the generation of antibodies against androstenedione presumably decreases circulating levels of androstenedione. This is thought to result in reduced negative feedback on the hypothalamic-pituitary-gonadal axis and increased gonadotropin secretion, which in turn improves fertility and fecundity. Indeed, ovandrotone albumin has been found to significantly increase luteinizing hormone levels throughout the estrous cycle in ewes.
This brief starts where responsible research should: with the source description of “Ovandrotone albumin” as immunogen and vaccine against androstenedione. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the general reference register because the source frames it as immunogen and vaccine against androstenedione. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Apr 27, 2022. The linked authority identifier is Q28209758. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1981 and 1983.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Ovandrotone albumin”, its source revision and the description used here.
- Expand the search: follow Ovandrotone albumin primary sources, Ovandrotone albumin archive and Ovandrotone research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Ovandrotone albumin”?
- What terminology or title could unlock a more precise catalogue search?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Ovandrotone albumin” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.